中国部分地区心房颤动住院病例回顾性调查

被引:219
作者
戚文航
机构
[1] 中华医学会心血管病分会
[2] 上海第二医科大学瑞金医院心内科
关键词
心房颤动; 流行病学研究; 抗心律失常药; 脑血管意外;
D O I
暂无
中图分类号
R541.7 [心律失常];
学科分类号
1002 ; 100201 ;
摘要
目的 了解中国心房颤动 (房颤 )患者年龄分布、病因 (或相关因素 )、房颤类型、脑卒中等流行病学特征及不同类型房颤的治疗现状。方法 对 1999~ 2 0 0 1年中国内地 4 1家医院诊断的心房颤动患者的住院病历进行回顾性分析和统计。结果  (1)共入选 92 97例 ,平均年龄 6 5 5岁 ,男女比为 13∶12。三年内房颤占同期心血管住院病人比例呈逐年上升趋势 ,平均 7 9%。随年龄增高病例数进行性递增。 (2 )房颤病因及相关因素统计 (单项 % ) ,老年 5 8 1% ,高血压 4 0 3% ,冠心病34 8% ,心衰 33 1% ,风湿性瓣膜病 2 3 9% ,特发性房颤 7 4 % ,心肌病 5 4 %和糖尿病 4 1%等。其中以高龄与高血压的组合最常见。本组患者中 2 / 3有心房增大 ,1/ 3有射血分数降低。 (3)房颤类型中阵发性占 33 7% ,持续性 16 7% ,持久性 4 9 5 %。 (4)阵发性房颤 5 6 4 %采用节律控制治疗 ,18 2 %用心室率控制方法 ,应用药物以胺碘酮、洋地黄制剂最多 ,其次为 β受体阻滞剂、普鲁帕酮等。(5 )慢性房颤 82 8%接受心室率控制治疗 ,常用药物为地高辛、β受体阻滞剂及钙拮抗剂。在持续性房颤患者中 ,试行复律者不足 1/ 2 ,其中 31 1%复律后可维持稳定窦性心律 ,应用药物以胺碘酮最多 ,其次为普鲁帕酮、奎尼丁、索他洛尔等。 (6 )本
引用
收藏
页码:36 / 39
页数:4
相关论文
共 9 条
[1]  
Conversion of Recent onset paroxysmal atrial fibrillation to normal sinus rhythm: The effect of no treatment and high-dose amiodarone. Cotter G,Blatt A,Kaluski E,et al. European Heart Journal . 1999
[2]  
Placebo-controlled randomized trial of warfarin and Aspirin for prevention of thromboembolic complications in chronic atrial fibrillation.The Copenhagen AFASAK study. Deterson P,Boysen G,Godtfredsen J,et al. The Lancet . 1989
[3]  
Prevalence, age,distribution and gender of patients with atrial fibrillation. Feinberg WM,Blackshear JL,Laupacis A,et al. Archives of Internal Medicine . 1995
[4]  
The risk for and severity of bleeding complications in elderly patients treated with warfarin. fihn SD,Callahan CM,Martin DC,et al. Annals of Internal Medicine . 1996
[5]  
The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the manitoba follow-up study. Krahn AD,Manfreda J,Tate RB,et al. The American Journal of Medicine . 1995
[6]  
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Fuster V,Ryden LE. Journalism Assn of Community College . 2001
[7]  
Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. Brannwald E. The New England Journal of Medicine . 1997
[8]  
Assessment of atrioventricular function ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: a randomized controlled study. Brignole M,Gianfranchi L,Menozzi C,et al. Circulation . 1997
[9]  
Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Pearce LA,Hart RG,Halperin JL. The American Journal of Medicine . 2000